SDC1 and Miyoshi myopathy: Immunotargeting of Syndecan-1/CD138 appears to be an appropriate and putatively successful approach for MM treatment, given the wealth of supportive experimental data and convincing preclinical results obtained by radioimmuno-targeting through a 213Bi-antibody conjugate [132].